FilingReader Intelligence
Tasly Pharmaceutical reports 789m yuan H1 profit, proposes dividend
August 15, 2025 at 10:40 AM UTC•By FilingReader AI
Tasly Pharmaceutical Group reported H1 2025 revenue of 4.29 billion yuan and net profit of 789.8 million yuan.
The company proposes a cash dividend of 2.1 yuan per 10 shares, representing 40.5% of consolidated net profit attributable to shareholders, pending shareholder approval.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SSE:600535•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Tasly Pharmaceutica Group publishes news
Free account required • Unsubscribe anytime